

## Thursday - 7<sup>th</sup> June 2018

[www.ebmt.org](http://www.ebmt.org)

# Friday - 8<sup>th</sup> June 2018

## III SESSION

### 09:00-10:45 State of the Art and perspectives in Congenital Bone Marrow Failure (joint)

*Chairs: JH. Dalle, E. Lanino*

State of the Art

*C. Dufour*

Role of mitochondrial defects in Fanconi anaemia:  
potential correlations between genotype and phenotype

*A. Savoia*

2018 Update on Diagnosis and Management of DBA

*M. Wlodarski*

Clinical Cases

*J. Zambrano, U. Koçak  
and G. Sezgin*

### 10:45-11:15 Coffee Break

## IV SESSION

### 11:15-13:00 (IDWP session) Progresses in treating infectious complications

*Chairs: S. Cesaro, M. Mikulska*

New treatment approach for Adenovirus

*T. Feuchtinger*

Progress in prophylaxis and treatment of mold infection

*K. Kalwak*

Prophylaxis and treatment of G neg infection

*M. Mikulska*

Clinical Cases

*F. Minniti, P. Palomo and  
P. Mensah-Glanowska*

### 13:00-14:00 Lunch Symposium kindly supported by Chimerix (joint)

#### **Adenovirus infection in Pediatric HSCT patients: Practice patterns and predictors of outcomes**

*Chair: S. Cesaro*

Adenoviral Infection Landscape in The Pediatric HSCT  
Patient - Review of Recent European Surveys

*S. Cesaro*

## Friday - 8<sup>th</sup> June 2018

---

Adenovirus Viral Burden is Associated with Mortality in Pediatric Allogeneic Hematopoietic Cell Transplant Recipients	<i>M. Zecca</i>
---	-----------------

---

Implications of Viral Load on The Pediatric HSCT Recipient - Results From a Single Center Cohort	<i>D. Deambrosis</i>
--	----------------------

---

### V SESSION

14:00-15:50

#### **New Development for the treatment of relapse in children with acute leukemia**

---

*Chairs: R. Meisel, A. Balduzzi*

---

Role of SCT in DNA repair disorders	<i>A. Gennery</i>
-------------------------------------	-------------------

---

New approaches in CART-cell therapy	<i>G. Lucchini</i>
-------------------------------------	--------------------

---

CART-cell against CD19 leukemia	<i>P. Bader</i>
---------------------------------	-----------------

---

CIK cells for preemptive immunotherapy	<i>P. Bader</i>
--	-----------------

---

Clinical Case	<i>J. Marsal</i>
---------------	------------------

---

15:50-16:15

#### **Coffee Break**

### VI SESSION

16:15-18:00

#### **Frontiers of Precision medicine**

---

*Chairs: M. Rabusin, D. Pagliara*

---

Genomic alterations in ALL relapses post allogeneic HSCT	<i>R. Meisel</i>
--	------------------

---

Impact of KIR typing in patients with HLA identical donors	<i>F. Babor</i>
--	-----------------

---

New insights in the importance of pharmacogenomics in the dose adjustment of the conditioning regimen	<i>M. Ansari</i>
---	------------------

---

Clinical Cases	<i>K. Kleinschmidt, M. Leoni and P. Svec</i>
----------------	--

---

# Saturday - 9<sup>th</sup> June 2018

## VII SESSION

### 09:00-10:20 **New developments in the diagnosis and treatment of immediate complications (I)**

*Chair: M. Krampere*

Endothelial associated diseases S. Corbacioglu

A novel method to generate MSC and its clinical options P. Bader

Clinical Cases E. Even-Or, S. Elgaz  
and Cs. Kassa

### 10:20-10:40 **Coffee Break**

## VIII SESSION

### 10:40-12:25 **New developments in the diagnosis and treatment of immediate complications (II - joint)**

*Chairs: C. Peters, F. Fagioli*

Gene therapy in PID/HLH C. Booth

Acute GVHD, incidence, treatment and outcome A. Bertaina

ECP for aGVHD A. Lawitschka

Clinical Cases F. Pavan, E. Brivio and  
S. González

### 12:25-12:40 **Closure**

*Chairs: P. Bader, A. Lankester, D. Hutt, S. Cesaro*

### 12:40-13:10 **Light lunch**